| 11-Jan-2016 | S | Vivimed Labs Ltd has informed BSE that the Board of Directors of the Company at its meeting held on January 11, 2016, inter alia, have approved/resolved/taken note of the following:
1. Approved the sub division proposal of Company's Equity Shares from the existing face value of Rs. 10/- per Equity Share to Rs. 2/- per Equity Share subject to the approval of Company's shareholders, which is proposed to be obtained through Postal Ballot & E-Voting.
SUB. :- Sub Division of equity shares of Vivimed Labs Limited (Scrip Code 532660)
Trading Members of the Exchange are hereby informed that, Vivimed Labs Ltd. has fixed the Record Date for the purpose of sub division of equity shares of the company.
DEMATERIALISED SECURITIES - ROLLING SETTLEMENT SEGMENT
COMPANY NAME & CODE
Vivimed Labs Ltd.
(532660)
RECORD DATE
08/04/2016
PURPOSE
Sub Division of existing equity shares from every ONE equity share of Rs.10/- each into FIVE equity shares of Rs.2/- each.
SUB-DIVIDED PAID-UP VALUE
Rs.2/-
SUB-DIVIDED PAID-UP VALUE W.E.F.
06/04/2016 DR-006/2016- 2017
Note:-
i. Trading members are hereby informed that the transactions in the equity shares (physical) of the aforesaid company in the Exit-Route Scheme will be for Rs. 2/- paid up w.e.f. 06/04/2016.
ii. ISIN No. INE526G01013 of Rs.10/- paid up will not be valid for transactions done on the Exchange on or after 06/04/2016.
iii. The new ISIN Number for Rs.2/- paid up will be informed to the market by a separate notice.
(As Per BSE Notice Dated on 18.03.2016)
I have examined all Share Transfer deeds, Memorandum of Transfers, Registers, Files and other Documents relating to M/s. VIVIMED LABS LIMITED maintained by M/s.Aarthi Consultants Pvt. Ltd., for the period from 1st April, 2017 to 30th September, 2017 for the purpose of issuing Certificate as per Regulation 40 (9) of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 and based on information provided by the Company I hereby certify.
A)that all certificates have been issued within thirty days of the date of lodgement for transfer, sub-division, consolidation, renewal, exchange or endorsement of calls/allotment monies during the period from 1st April, 2017 to 30th September, 2017 excepting those rejected on technical grounds.
(As per BSE Announcement date on 24/10/2017) | 08-Apr-2016 | |
| 30-May-2018 | D | Vivimed Labs Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 30, 2018, inter alia, has recommended, subject to the approval of shareholders, payment of Dividend of Rs. 0.40/- (Forty paise) per equity share of Rs. 2/- each (20%), to the equity shareholders of the Company for the Financial Year 2017-2018. The said dividend, if approved by shareholders, will be credited /despatched to those members entitled thereto as per record date/Book closure date to be decided subsequently. | 19-Sep-2018 | |
| 28-May-2017 | D | Vivimed Labs Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 27, 2017,inter alia, has recommended, subject to the approval of shareholders, payment of Dividend of Rs. 0.40/- (Forty paise) per equity share of Rs. 2/- each (20%), to the equity shareholders of the Company for the Financial year 2016-2017. The said dividend, if approved by shareholders, will be credited/despatched to those members entitled thereto as per record date/Book closure date to be decided subsequently. | 21-Sep-2017 | |
| 30-May-2014 | D | Vivimed Labs Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 29, 2014, inter alia, has recommended a dividend of Rs. 3/- (30%) per equity share of Rs.10/- each for the financial year ended March 31, 2014 and the dividend if approved by share holders in ensuing annual general meeting. | 24-Sep-2014 | |
| 31-May-2013 | D | Vivimed Labs Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 30, 2013, inter alia, has recommended a dividend of Rs. 3/- (30%) per equity share of Rs.10/- each for the financial year ended March 31,2013 and the dividend if approved by share holders in ensuing annual general meeting, will be credited /despatched to those members entitled thereto as per record date/Book closure date to be decided subsequently. | 24-Sep-2013 | |
| 31-May-2012 | D | Vivimed Labs Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 30, 2012, inter alia, has recommended :
A final dividend of Rs. 3/- per share (30%) on equity shares for the financial year 2011-12. | 21-Sep-2012 | |
| 28-May-2011 | D | Vivimed Labs Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 27, 2011, inter alia, has taken following decisions:
Recommended a final dividend of Rs. 2/- per equity share for the financial year 2010-11. | 26-Sep-2011 | |
| 16-Aug-2010 | D | Vivimed Labs Ltd has informed BSE that the Board of Directors of the Company at its meeting convened on August 14, 2010 and adjourned to August 16, 2010, inter alia, has decided to recommend a divided of Rs. 1.50/- (15%) per share on 99,64,904 equity share of nominal value Rs. 10 each aggregating to Rs. 1,49,47,356, subject to approval of the shareholders at their Annual General Meeting. | 09-Sep-2010 | |
| 01-Jul-2009 | D | Vivimed Labs Ltd has informed BSE that the Board of Directors of the Company at its meeting held on June 30, 2009, inter alia, has recommended a dividend of Rs 1.5 per Equity Share (15%) amounting to Rs 141 lakhs plus tax on dividend of Rs 23.96 lakhs. | 24-Sep-2009 | |
| 29-Jun-2008 | D | Vivimed Labs Ltd has informed BSE that the Board of Directors of the Company at its meeting held on June 28, 2008, inter alia, has transacted the following:
The Board recommended payment of 10% dividend (Re 1/- per Fully Paid Equity Share of the Company). | 22-Sep-2008 | |
| 24-Feb-2024 | BC | Resignation of CFO | 23-Feb-2024 | |
| 31-Jan-2024 | BC | VIVIMED LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2024 inter alia to consider and approve Pursuant to Regulation 29 of SEBI (Listing Ob | 14-Feb-2024 | |
| 28-Oct-2023 | BC | VIVIMED LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2023 inter alia to consider and approve Pursuant to Regulation 29 of SEBI (Listing Ob | 14-Nov-2023 | |
| 18-Oct-2023 | BC | The Board of Directors of the Company at its meeting held on October 18, 2023 inter alia, have approved / resolved/ taken note of the following:
1. Directors Report for the financial year ended 31. | 13-Nov-2023 | |
| 18-Oct-2023 | BC | Annual General Meeting | 08-Nov-2023 | |